tiprankstipranks
Trending News
More News >
Arcus Biosciences Inc (RCUS)
NYSE:RCUS
US Market
Advertisement

Arcus Biosciences (RCUS) AI Stock Analysis

Compare
488 Followers

Top Page

RCUS

Arcus Biosciences

(NYSE:RCUS)

Rating:54Neutral
Price Target:
$12.00
▲(3.81% Upside)
Arcus Biosciences' stock score is primarily influenced by its strong technical momentum, despite financial challenges and a weak valuation. The company's robust revenue growth is a positive, but profitability and cash flow issues need to be addressed for long-term stability. The technical analysis suggests potential for short-term gains, but caution is advised due to overbought conditions.
Positive Factors
Clinical Progress
The PEAK-1 trial has initiated enrollment and will evaluate casdatifan and cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma, indicating progress in research and development.
Financial Position
Arcus Biosciences ended the quarter with significant cash and investments, expected to fund operations through key initial readouts, providing a strong financial position.
Product Differentiation
New analysis supports the clinical relevance of erythropoietin suppression by casdatifan, which differentiates it from competitors, bolstering confidence in its potential.
Negative Factors
Commercial Challenges
Skepticism has weighed on sentiment due to Gilead's commercial opt-out and overall uncertainty.
Competitive Pressures
Difficulties competing with established players like Merck and Bristol and the considerable cost of running necessary studies pose challenges.
Market Skepticism
Arcus faces challenges in achieving its vision due to prescriber inertia and strong skepticism towards its PD-1 zimberelimab.

Arcus Biosciences (RCUS) vs. SPDR S&P 500 ETF (SPY)

Arcus Biosciences Business Overview & Revenue Model

Company DescriptionArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
How the Company Makes MoneyArcus Biosciences generates revenue primarily through the development and commercialization of its pharmaceutical products. The company's revenue model includes potential milestone payments from collaborations with larger pharmaceutical companies, royalties from product sales once therapies are approved, and funding from strategic partnerships. Significant partnerships with established biopharma entities can enhance its financial stability and provide upfront payments, research funding, and shared development costs. Additionally, as the company advances its drug candidates through clinical trials, it may realize milestone payments tied to achieving specific development stages, thus contributing to its overall earnings.

Arcus Biosciences Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Breaks down revenue by different business units or product lines, highlighting which areas are driving growth and which may need strategic adjustments.
Chart InsightsArcus Biosciences' revenue from License and Development Services shows volatility, with a notable spike in Q1 2024. However, the latest earnings call highlights a decline in quarterly revenue, attributed to collaboration dynamics with Gilead. Despite this, Arcus maintains a strong cash position and is strategically focused on advancing its casdatifan program, targeting a significant market opportunity in RCC. The company's collaborations, particularly with AstraZeneca, and rapid trial enrollments underscore its potential for future growth, though pipeline reprioritization poses some risk.
Data provided by:Main Street Data

Arcus Biosciences Earnings Call Summary

Earnings Call Date:Aug 06, 2025
(Q1-2025)
|
% Change Since: |
Next Earnings Date:Nov 11, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted Arcus Biosciences' strong financial position and strategic focus on the casdatifan program, supported by significant investor and investigator enthusiasm. However, there were challenges related to pipeline prioritization and a decline in quarterly revenue.
Q1-2025 Updates
Positive Updates
Strong Financial Position and Capital Strategy
Arcus Biosciences reported a strong cash position with $1 billion in cash and investments. The company completed a $150 million equity financing in February 2025, ensuring sufficient funding for operations through pivotal readouts for key programs.
Casdatifan Program Advancements
Arcus remains focused on the casdatifan program, with multiple cohorts and combination studies ongoing. The program's data has been selected for oral presentation at ASCO, highlighting its importance and potential in RCC treatment.
Positive Enrollment and Investigator Enthusiasm
The Phase 3 PRISM-1 trial in pancreatic cancer is enrolling rapidly, expected to complete enrollment by the end of 2025. Investigator enthusiasm for the PEAK-1 study is high, supported by prior monotherapy cohort data.
Strategic Collaborations
Arcus is collaborating with AstraZeneca to combine casdatifan with AstraZeneca's anti-PD-1 anti-CTLA-4 bispecific antibody, volrustomig, for a TKI-free treatment option in first-line RCC, enhancing strategic development capabilities.
Negative Updates
Pipeline Reprioritization and Program Decisions
Arcus is not moving forward with the A2 receptor antagonist etruma program at this time, reflecting ongoing pipeline reprioritization decisions.
Revenue Decline
Arcus reported a decrease in GAAP revenue for the first quarter of 2025, at $28 million compared to $36 million in the fourth quarter of 2024.
Company Guidance
In the Arcus Biosciences First Quarter 2025 Earnings Call, the company provided guidance on several key metrics and strategic focuses. The cash runway is bolstered by $1 billion in cash and investments, ensuring funding through pivotal readouts for their late-stage programs, such as casdatifan (cas), domvanalimab (dom), and quemli. The projected 2025 revenue is expected to be between $75 million and $90 million, primarily driven by collaborations with Gilead. The company emphasized the advancement of cas, particularly through the PEAK-1 Phase 3 trial, expected to enroll 700 patients quickly due to investigator enthusiasm and strategic site transitions. Additionally, the company highlighted upcoming data presentations, including cas plus cabo data at ASCO, and their collaboration with AstraZeneca to develop TKI-free regimens in earlier RCC treatment lines. The R&D expenses for the first quarter were $122 million, with a peak in development expenses anticipated for 2025, and a decline expected in 2026 and 2027. The company is also focusing on prioritizing pipeline investments and leveraging strategic collaborations.

Arcus Biosciences Financial Statement Overview

Summary
Arcus Biosciences is experiencing robust revenue growth, but profitability and cash flow challenges persist. The company maintains a low leverage position, which is positive, but needs to address its operational inefficiencies to improve financial health.
Income Statement
45
Neutral
Arcus Biosciences has shown significant revenue growth in the TTM period with an 85.82% increase, indicating strong top-line expansion. However, the company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins across all periods, reflecting ongoing operational challenges.
Balance Sheet
50
Neutral
The company's debt-to-equity ratio is relatively low at 0.20 in the TTM period, suggesting a conservative leverage position. However, the negative return on equity indicates that the company is not currently generating positive returns for shareholders, which is a concern for long-term sustainability.
Cash Flow
40
Negative
Arcus Biosciences has experienced positive free cash flow growth in the TTM period, but the operating cash flow remains negative, which could impact liquidity. The free cash flow to net income ratio is slightly above 1, indicating that cash flows are aligned with reported earnings, but the negative operating cash flow to net income ratio suggests operational inefficiencies.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue262.00M258.00M117.00M112.00M383.00M78.00M
Gross Profit262.00M258.00M117.00M112.00M383.00M78.00M
EBITDA-282.00M-269.00M-291.00M-258.00M59.00M-120.00M
Net Income-306.00M-283.00M-307.00M-267.00M53.00M-123.00M
Balance Sheet
Total Assets1.07B1.15B1.09B1.34B1.59B772.29M
Cash, Cash Equivalents and Short-Term Investments911.00M978.00M759.00M1.14B681.30M735.09M
Total Debt109.00M60.00M11.00M120.00M116.89M15.24M
Total Liabilities526.00M665.00M633.00M688.00M750.45M269.99M
Stockholders Equity549.00M485.00M462.00M657.00M841.45M502.30M
Cash Flow
Free Cash Flow-342.00M-176.00M-330.00M426.00M-282.25M108.11M
Operating Cash Flow-339.00M-170.00M-306.00M438.00M-256.17M111.17M
Investing Cash Flow191.00M-84.00M194.00M-413.00M-3.87M-434.37M
Financing Cash Flow240.00M277.00M33.00M33.00M237.34M438.68M

Arcus Biosciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price11.56
Price Trends
50DMA
9.58
Positive
100DMA
9.16
Positive
200DMA
10.89
Positive
Market Momentum
MACD
0.46
Negative
RSI
70.53
Negative
STOCH
83.94
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RCUS, the sentiment is Positive. The current price of 11.56 is above the 20-day moving average (MA) of 10.27, above the 50-day MA of 9.58, and above the 200-day MA of 10.89, indicating a bullish trend. The MACD of 0.46 indicates Negative momentum. The RSI at 70.53 is Negative, neither overbought nor oversold. The STOCH value of 83.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RCUS.

Arcus Biosciences Risk Analysis

Arcus Biosciences disclosed 60 risk factors in its most recent earnings report. Arcus Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Arcus Biosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$814.27M-43.63%-13.05%
54
Neutral
$1.15B-50.34%6.07%-2.28%
52
Neutral
271.44%26.65%
51
Neutral
$7.91B-0.36-41.70%2.23%23.45%-1.86%
43
Neutral
$1.00B2.31-41.00%-429.68%
42
Neutral
$460.53M-73.44%-1.07%
33
Underperform
$734.71M-109.12%7.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RCUS
Arcus Biosciences
11.56
-4.16
-26.46%
AVXL
Anavex Life Sciences
9.36
4.21
81.75%
SYRE
Spyre Therapeutics
16.99
-10.97
-39.23%
REPL
Replimune Group
5.81
-4.56
-43.97%
SANA
Sana Biotechnology
2.98
-2.06
-40.87%
VERV
Verve Therapeutics
11.13
5.53
98.75%

Arcus Biosciences Corporate Events

Executive/Board ChangesShareholder Meetings
Arcus Biosciences Holds Annual Stockholders Meeting
Neutral
Jun 12, 2025

On June 10, 2025, Arcus Biosciences held its annual meeting of stockholders, where key proposals were voted on, including the election of Class I directors and the ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025. Additionally, the Board of Directors revised the Non-Employee Director Compensation Program, reflecting the company’s ongoing efforts to align its governance and compensation practices with industry standards.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 05, 2025